The Comparative Effectiveness Between ARNI and ACE Inhibitor/ARB Medication in Patient With HFrEF

Heart Failure Clinical Trial

— PARADE-HF  

Official title:

The Comparative Effectiveness Study Between ARNI and ACE Inhibitor/ARB Medication in Patient With Heart Failure With Reduced Ejection Fraction Using the Nationwide Population Based Real World Registry of Korean Heart Failure

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05329727
• Other study ID #: CR321358
• Status: Recruiting
• Start date: February 18, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: July 2023
• Source: Wonju Severance Christian Hospital
• Contact: Dong-Hyuk Cho, MD,PhD
• Phone: 82-33-741-0916
• Email: why012[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aimed to evaluate the effectiveness, safety, and cost-effectiveness of ARNI and ACEi/ARBs in real-world practice. This study could find out what the unmet medical needs are in real world practice. Furthermore, this study will be helpful to establish the healthcare policy reimbursement policy or clinical practice guideline for HF regarding HF medications to reduce the burden of HF in Korea.

Description:

Despite developments and improvements in treatment strategies, heart failure (HF) remains a significant socioeconomic burden and leads to individual health problems due to its high mortality and readmission rates. The latest 2016 European Society of Cardiology (ESC) guideline recommends pharmacological treatment indicated in patients with symptomatic HF with reduced ejection fraction. As the Class I level, the ESC guideline recommends 'ACEI, ARB, ARNI, BB, MRA, Diuretics'. Guideline-directed medication therapy (GDMT) significantly improved the survival of HF, particularly heart failure with reduced ejection fraction (HFrEF). However, various registry studies demonstrated that HFrEF patients are frequently undertreated. The gap exists between the ideal guideline and the current practice of HF treatment. According to the observational nationwide study using the Korean National Health Insurance Claims database, still, 28.6% of elderly heart failure patients did not receive evidence-based treatment. To reduce the various burdens of HF at the patient and society level, the right understanding of the disease and a nationwide systematic approach are needed. Recently, more data have emerged to support an expanded role for ARNIs in patients with HFrEF. These data include their use as a de novo therapy in some patients naive to ACEIs or ARB therapies, evidence for rapid improvement in patient-reported outcome measures, and the demonstration of a reverse-remodeling effect of ARNIs in chronic HFrEF, independent of background therapy with ACEIs/ARBs. However, the use of ARNI is still under expectation. Clinical trials showed a fabulous result with the use of ARNI in HFrEF patients, however, real-world data is still lacking. In Korea, the use of ARNI is increasing, however, the exact use of ARNI is unknown, and only limited data reported the prescription pattern and outcomes of ARNI in HFrEF patients. Korea has an obligatory public health insurance system, the term of the Korean National Health Insurance Service (NHIS) with which more than 97% of people are affiliated. All claim data is electronically recorded and can be investigated for research purposes with the approval of the Research Ethics Committee. The use of medications, dosage, cost, and the effect on HF outcomes are assessable using the Korean NHIS database. Previous studies about HF using the NHIS database have several limitations. They were conducted in small research groups, and the operational definition of each study was different, and no studies were conducted after sufficient discussions with HF expert opinions from the Korean Society of Heart Failure. This study aimed to evaluate the effectiveness, safety, and cost-effectiveness of ARNI and ACEi/ARBs in real-world practice. This study could find out what the unmet medical needs are in real-world practice. Furthermore, this study will be helpful to establish the healthcare policy reimbursement policy or clinical practice guidelines for HF regarding HF medications to reduce the burden of HF in Korea. This is a non-interventional retrospective cohort study. This study will collect primary data and secondary use data. The data will originate from the NHIS database. Clinical characteristics (age, sex, BMI, WC, lipid profile, LFT, physical activity) will be investigated. The treatment patterns are to be summarized using the proportion of patients with good guideline adherence. Finally, it will compare the clinical outcomes (hospitalization rate, cardiovascular and all-cause mortality) and medical costs of patients groups who were treated with ARNI and without ARNI. This study will collect primary data and secondary use data in patients with HF between 2017 and 2021. Data sources might include socioeconomic status, abstracts of primary clinical records, electronic medical records, prescription drug files, laboratory reports, and questionnaires for health behaviors. Concomitant or prior medications entered into the database will be coded using the NHIS Reference List. Medical history/current medical conditions will be coded using ICD-10 codes. The Kaplan-Meier will be used for the survival curve to analyze the primary endpoints (all-cause mortality, CV mortality, or first/recurrent any hospitalization ) and the related results. Normally distributed continuous data are reported as mean ± standard deviation, while non-parametric data are reported as median with interquartile range in brackets. Categorical data are reported as numbers with percentages in brackets. Comparisons between continuous variables were made using independent t-tests, while chi-square tests were made for comparisons between categorical variables, with posthoc correction for tests including more than two groups. Propensity score matching (maximum 1:5) will be performed for those who had used ARNI and those who had not (ACEi/ARBs). The propensity score analysis balances covariates between study groups of observational data using a propensity score, which is the conditional probability of assignment to a particular group given observed covariates only. The investigators will derive the propensity score model from a multiple logistic regression that included age, sex, and underlying comorbidities. A stratified Cox proportional hazards regression model for matched data will be used to evaluate the relation between the treatments and study outcomes (mortality and/or first/recurrent any hospitalization).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000000
• Est. completion date: December 31, 2025
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HF patients were defined as those with "heart failure" according to the disease code in the main code and the sub-code in the claims data. HF patients who were assigned the following KCD-6 disease codes were considered as: "hypertensive heart disease with (congestive) HF" (I11.0), "hypertensive heart and renal disease with (congestive) HF" (I13.0), "hypertensive heart and renal disease with both (congestive) HF and renal failure" (I13.2), and "HF" (I50) including "congestive HF" (I50.0), "LV failure" (I50.1), and "HF and unspecified" (I50.9).
• HFrEF patients were defined with the following KCD-6 disease codes: "Congestive heart failure with systolic dysfunction"(I5004), "Left ventricular failure"(I501), "Ischaemic cardiomyopathy"(I22.5), "Dilated cardiomyopathy" (I420). Hospitalized heart failure is defined as the HF disease code and admission.

Exclusion Criteria:

• Less than 18 years old
• In case where investigators determine it's inappropriate to be included in the study as per investigators' clinical judgment

Related Conditions & MeSH terms

• Heart Failure
• Mortality

Intervention

Drug:
• Angiotensin receptor neprilysin inhibitor (ARNI)
The group with ARNI was defined as patients with HFrEF took ARNI more than 3 months
• Renin-Angiotensin System Inhibitor (RAS inhibitor)
The group with RAS inhibitor was defined as patients with HFrEF took RAS inhibitor more than 3 months

Locations

Country	Name	City	State
Korea, Republic of	Yonsei University Wonju College of Medicine	Wonju	Gangwondo

Sponsors (1)

Lead Sponsor	Collaborator
Wonju Severance Christian Hospital

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (6)

Chang PP, Wruck LM, Shahar E, Rossi JS, Loehr LR, Russell SD, Agarwal SK, Konety SH, Rodriguez CJ, Rosamond WD. Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005-2014): ARIC Study Community Surveillance. Circulation. 2018 Jul 3;138(1):12-24. doi: 10.1161/CIRCULATIONAHA.117.027551. Epub 2018 Mar 8. — View Citation

Cho DH, Yoo BS. Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection Fraction. Heart Fail Clin. 2021 Jul;17(3):315-326. doi: 10.1016/j.hfc.2021.03.002. — View Citation

Choi EK. Cardiovascular Research Using the Korean National Health Information Database. Korean Circ J. 2020 Sep;50(9):754-772. doi: 10.4070/kcj.2020.0171. Epub 2020 May 20. — View Citation

Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018 Feb 10;391(10120):572-580. doi: 10.1016/S0140-6736(17)32520-5. Epub 2017 Nov 21. — View Citation

Lee JH, Lim NK, Cho MC, Park HY. Epidemiology of Heart Failure in Korea: Present and Future. Korean Circ J. 2016 Sep;46(5):658-664. doi: 10.4070/kcj.2016.46.5.658. Epub 2016 Sep 28. — View Citation

Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR, Gottdiener JS, Psaty BM, Vasan RS. Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction. JACC Heart Fail. 2018 Aug;6(8):678-685. doi: 10.1016/j.jchf.2018.03.006. Epub 2018 Jul 11. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidence rate (%) of composite endpoint including all-cause mortality or hospital readmission	all cause mortality: death due to any cause.; Hospital readmission: any readmission	12 months
Primary	The medical cost (won) of medical care	The total medical cost of hospitalization due to HF and visitation to the outpatients clinic due to HF	12 months